Overview

• Immuneering Q3 net loss of $15 mln beats analyst expectations

• Company raised $225 mln, extending cash runway into 2029

• Reported 86% overall survival at 9 months in pancreatic cancer trial

Outlook

• Company expects cash runway to fund operations into 2029

• Immuneering to report updated survival data in 1H 2026

Result Drivers

• FINANCING SUCCESS - Raised $225 mln, including $25 mln from Sanofi, extending cash runway into 2029

• R&D expenses for the third quarter of 2025 were $10.9 million, compared with $11.3 million for the third quarter of 2024

• PATIENT RESPONSES - Case studies show complete response and curative intent treatment in pancreatic cancer patients

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Immuneering Corp is $13.50, about 50.1% above its November 11 closing price of $6.74

Press Release: ID:nGNX80G5Ql

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)